Hcw biologics reports second quarter 2024 financial results and business highlights - correction

This release has made a correction to a release issued under the same headline on august 14, 2024, by hcw biologics, inc. (nasdaq: hcwb), to show the amount included in the condensed interim balance sheet for cash and cash equivalents as of december 31, 2023 as $3,595,101, not $95,101 as previously stated. the full text of the corrected release is as follows: miramar, fla.
HCWB Ratings Summary
HCWB Quant Ranking